Диссертация (1139917), страница 15
Текст из файла (страница 15)
Chedid // J Interferon Cytokine Res. – 1996. – № 16(2). – Р. 169–78.50.Bahr,GM.Immunopharmacologicalactivitiesandclinicaldevelopment of muramyl peptides with particular emphasis on murabutide / GMBahr, E. Darcissac, D. Bevec, P. Dukor, L. Chedid / Int J Immunopharmacol. – 1995.– № 17(2).
– Р. 117–31.51.Barnich N. Membrane recruitment of NOD2 in intestinal epithelial cellsis essential for nuclear factor-{kappa}B activation in muramyl dipeptide recognition/ N. Barnich, JE. Aguirre, HC. Reinecker, R. Xavier, DK. Podolsky // J. Cel.l Biol.– 2005. – № 170(1) P. 21–6.52.Barton DHRCJ. Synthesis of biologically active carbocyclic analogs ofN-acetylmuramyl-}-L-alanyl-D-isoglutamine (MDP) / DHRCJ. Barton, P. Dalco,SD. Géro, B. Quiclet-Sire, P. Stütz // J. Org. Chem. – 1989. – № 54 – P. 3764–66.53.Baschang G. Muramyl peptides and lipopeptides: studies towardsimmunostimulants / G.
Baschang // Tetrahedron. – 1989. – № 45(20) – P. 6331–60.54.Bevins, CL. Decreased Paneth cell defensin expression in ileal Crohn’sdisease is independent of inflammation, but linked to the NOD2 1007fs genotype /CL. Bevins, EF. Stange, J. Wehkamp // Gut. – 2009 – № 58(6) – P. 882– 3.discussion 883–4.55.Bertin J. Human CARD4 protein is a novel CED-4/Apaf-1 cell deathfamily member that activates NF-kappa B / J. Bertin, WJ.
Nir, CM. Fischer, OV.Tayber, PR. Errada, JR. Grant, JJ. Keilty, ML. Gosselin, KE. Robison, GH. Wong,MA. Glucksmann, PS. DiStefano. //J. Biol. Chem. – 1999. – № 274(19) – P. 12955–8.56.Beutler B.A. TLRs and innate immunity. / Blood – 2009. – № 113 – P.1399–1407.57.Biberstine K.J. Peptidoglycan fragments decrease food intake and bodyweight gain in rats. / K.J.
Biberstine, R.S. Rosenthal. // Infect. Immun. –1994. – №62(8) – P. 3276–328112658.Biswas A. Nod2: a key regulator linking microbiota to intestinalmucosal immunity / A. Biswas, T. Petnicki-Ocwieja, K.S. Kobayashi. // J. Mol.Med. (Berl) – 2012. –№ 90 (1) – P. 15–24.59.Boyle JP. Insights into the molecular basis of the NOD2 signallingpathway / JP. Boyle, R.
Parkhouse, TP. Monie. // Open Biology. – 201 4– № 4 (12)– P. 140-178.60.Bouma, G. The immunological and genetic basis of inflammatorybowel disease / G. Bouma, W. Strober // Nat Rev Immunol – 2003. – № 3(7) – P.521–33.61.Bush, K. Tackling antibiotic resistance. // Nat Rev Microbiol – 2011–№9.
– P. 894–89662.Cai YLC-C. Facile approach to 2-acetoamido-2-deoxy-b-D-pyranosidevia a furanosyl oxazoline / YLC-C. Cai, D. Bundle // Org. Lett. – 2005. – № 7 – P.4021–24.63.Cai YLC-C. Concise and efficient synthesis of 2-acetoamido-2-deoxy-b -D- hexopyranosides of diverse aminosugars from 2-acetoamido-2-deoxy-b-Dglucose / HBR. Cai, D. Bundle // J.
Org. Chem. – 2009. – № 74 – P. 580–89.64.Casadevall A. A new synthesis for antibody-mediated immunity / A.Casadevall, L.A. Pirofski. // Nat. Immunol. – 2012. – № 13 (1): – P. 21–28.65.Cduk RGG. Synthesis of cyclopropanoid analogues of N-acyl-muramyldipeptides as potential immunostimulants / RGG. Cduk // Tetrahedron –2004. – № – P. 60 2201–11.66.Chedid, LA. Biological activity of a new synthetic muramyl peptideadjuvant devoid of pyrogenicity / LA. Chedid, MA. Parant, FM, Audibert, GJ,Riveau, FJ. Parant, E. Lederer, JP.
Choay, PL. Lefrancier // Infect Immun. –1982. –№ 35(2). – Р. 417–24.67.Chen CM. Reciprocal cross-talk between Nod2 and TAK1 signalingpathways / CM. Chen, Y. Gong, M. Zhang, JJ. Chen // J. Biol. Chem. – 2004. – №279(24) – P. 25876–82.12768.Chuai X. Poly(I:C)/Alum mixed adjuvant priming enhances HBVsubunit vaccine-induced immunity in mice when combined with recombinantadenoviral-based HBV vaccine boosting. / X. Chuai, H. Chen, W.
Wang et al. //PLoS ONE –2013. –№ 8 (1) –Art e54126.69.Correa R.G. Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innateimmunity and inflammatory diseases. / R.G. Correa, S. Milutinovic, J.C. Reed. //Biosci Rep – 2012. – №32 – P. 597–608.70.Cong Y. A dominant, coordinated T regulatory cell-IgA response to theintestinal microbiota. / Y. Cong, T. Feng, K. Fujihashi et al. // Proc. Natl. Acad. Sci.USA 2009. – №106 (46) – P. 19256–19261.71.Couturier-Maillard A. NOD2-mediated dysbiosis predisposes mice totransmissible colitis and colorectal cancer.
/ A. Couturier-Maillard, T. Secher, A.Rehman. // J. Clin. Invest. – 2013 – №123 (2) – P. 700–71172.Daemen, T. In vitro activation of rat liver macrophages to tumoricidalactivity by free or liposome-encapsulated muramyl dipeptide / T. Daemen, A.Veninga, FH. Roerdink, GL.
Scherphof // Cancer Res. – 1986. –№ 46(9) – Р. 4330–5.73.Danklmaier JHH. Synthesis of acyclic analog of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP) / JHH.Danklmaier // Liebigs. Ann. Chem. – 1990. –P. 145–50.74.Darcissac, EC. The synthetic immunomodulator murabutide controlshuman immunodeficiency virus type 1 replication at multiple levels in macrophagesand dendritic cells / EC. Darcissac, MJ. Truong, J. Dewulf, Y.
Mouton, A. Capron,GM. Bahr // J. Virol. – 2000. – № 74(17). – Р. 7794–802.75.Darcissac, EC. Selective induction of CD11a, b, c // CD18 and CD54expression at the cell surface of human leukocytes by muramyl peptides / EC.Darcissac, GM. Bahr, MA. Parant, LA. Chedid, GJ Riveau // Cell. Immunol. – 1996.– № 169(2). – Р.294–301.76.Dreesman, GR. Antibody to hepatitis B surface antigen after a singleinoculation of uncoupled synthetic HBsAg peptides / GR. Dreesman, Y. Sanchez, I.128Ionescu-Matiu, JT. Sparrow, HR.
Six, DL. Peterson, FB. Hollinger, JL. Melnick //Nature. – 1982. – № 295(5845). – Р. 158–60.77.Dormitzer P.R. Structural vaccinology starts to deliver. / P.R.Dormitzer, G. Grandi, R. Rappuoli. // Nat. Rev. Microbiol. – 2012 – № 10 – P. 807–81378.Dukor PTL, Baschang G. Immunostimulants /PTL. Dukor, G.Baschang // Ann. Rep. Med. Chem. – 1979.
– № 14 – P. 146–67.79.Dzierzbicka KKAM. Muramyl peptid-synthesis and biological activity/ KKAM. Dzierzbicka. // Polish. J. Chem. – 2003 – № 77 – P. 373–95.80.Dzierzbicka KKAM. Synthesis of muramyl dipeptide conjugated withacridine derivatives, showing anti-HIV-1 and anticancer activity / KKAM.Dzierzbicka, B. Wysocka-Skrzela, AS. Kolodziejczyk // Pol J Chem. – 1994. – №68 – P.
37–45.81.Dzierzbicka KKAM. Synthesis and antitumor activity of conjugates ofmuramyldipeptide, normuramyldipeptide, and desmuramylpeptides with acridine/acridone derivatives / KKAM. Dzierzbicka // J Med Chem. –2001. – № 44 – P.3606-15.82.Ellouz, F. Minimal structural requirements for adjuvant activity ofbacterial peptidoglycan derivatives / F. Ellouz, A. Adam, R. Ciorbaru, E. Lederer //Biochem Biophys Res Commun. – 1974. – № 59(4). – Р. 1317–25.83.Fairbrother WJ. The PYRIN domain: a member of the death domain-fold superfamily / WJ. Fairbrother, NC.
Gordon, EW. Humke, KM. O’Rourke, MA.Starovasnik, JP. Yin, VM. Dixit. // Protein Sci. – 2001. – № 10(9) – P. 1911–8.84.Ferraro B. Clinical applications of DNA vaccines: current progress / B.Ferraro, M.P. Morrow, N.A. Hutnick N.A. et al. // Clin. Infect. Dis. –2011. –№ 53(3)– P. 296–302.85.Ferrier R. Unsaturated carbohydrates. Part 21.
A carbocyclic rongclosure of a hex-5- enopyrasnoside derivative /R. Ferrier. // J. Chem. Soc, PerkinTrans. – 1979. – № 1 – P. 1455–58.12986.Farzi A. Synergistic effects of NOD1 or NOD2 and TLR4 activation onmouse sickness behavior in relation to immune and brain activity markers / A. Farzi,F. Reichmann, A. Meinitzer, R.
Mayerhofer et al. // Brain. Behav. Immun. – 2015.– № 44 – P. 106–120.87.Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis / C.Fiocchi // Gastroenterology. – 1998. – № 115(1) – P. 182–205.88.FlowersHMJRW.Thesynthesisof2-acetamido-3-O-(D-1-caroboxymethyl)-2-deoxy-a-D-glucose (N-acetylmuramic acid) and of benzylglycoside derivatives of 2-amino-2-O-(D-)1- carboxymethyl)-2-deoxy-D-glucose(muramic acid) / HMJRW. Flowers // J. Org. Chem.
–1963/ – № 28 – P. 2983–86.89.Freund, J. Sensitization and antibody formation after injection oftubercle bacilli and paraffin oil / J. Freund, J. Casals, EP Hismer // Proc Soc ExpBioi Med. – 1937. – Р. 37–509.90.Fritz JH. Synergistic stimulation of human monocytes and dendriticcells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists.
/ JH. Fritz,SE. Girardin, C. Fitting, C. Werts, D. Mengin-Lecreulx, M. Caroff, JM. Cavaillon,DJ Philpott, M. Adib-Conquy // Eur J Immunol. – 2005 – Aug – № 35(8) – P. 245970.91.Fukuda TKS. Synthesis of immunologically active muramyl dipeptidederivatives containing a quinonyl moiety via aminoacyl intermediates / TKS.Fukuda, H. Yukimasa, I. Imada, M. Fujino, I. Azuma, Y. Yamamura // Chem PharmBull. – 1981. – № 29 – P. 2215–21.92.Fukuyama Y.
Novel vaccine development strategies for inducingmucosal immunity / Y. Fujkuyama, D. Tokuhara, K. Kataoka et al. // Expert Rev.Vaccines – 2012 –№ 11 (3) – P. 367–379.93.Gee M.L. Imaging the action of antimicrobial peptides on livingbacterial cells / M.L. Gee, M. Burton, A. Grevis-James. // Sci. Rep. – 2013. – № 3 –Art 1557.94.Gero SSB. Dipeptide und deren Herstellung German / SSB. Gero, P.Dalko, M. Philippe // Pat Appl, DE.
– 1986.13095.Gigg RCPM. A synthesis of muramic acid / RCPM. Gigg, CD. Warren// J. Chem. Soc. – 1965. – № 46 – P. 2975–77.96.Girardin, SE. Nod1 detects a unique muropeptide from gram-negativebacterial peptidoglycan / SE. Girardin, IG. Boneca, LA. Carneiro, А. Antignac,Jehanno, M. Viala, J. Tedin, K. Taha, MK. Labigne, A. Zathringer, U. Coyle, AJ.DiStefano, PS. Bertin, J. Sansonetti, PJ. Philpott // Science.
– 2003. – № 300(5625).– Р. 1584–7.97.Girardin SE. Peptidoglycan molecular requirements allowing detectionby Nod1 and Nod2 / SE. Girardin, LH. Travassos, M Herve, D. Blanot, IG. Boneca,DJ. Philpott, PJ. Sansonetti, D. Mengin- Lecreulx // J Biol Chem. – 200398.Goasduff, T. The transcriptional response of human macrophages tomurabutide reflects a spectrum of biological effects for the syntheticimmunomodulator / T. Goasduff, EC.
Darcissac, V. Vidal, A. Capron, GM. Bahr /Clin Exp Immunol. – 2002. – № 128(3). – Р. 474–82.99.Gobec, SUU. Synthesis of new phosphonoamidate and phosphinamidedesmuramyldipeptide analogs / SUU. Gobec // Lett Pept Sci. – 1998. – № 5 – P.109–14.100.Gobec S. Synthesis and biochemical evaluation of some novel N- acylphosphono- and phosphinoalanine derivatives as potential inhibitors of the Dglutamic acid- adding enzyme / S. Gobec, U. Urleb, G.
Auger, D. Blanot //Pharmazie. – 2001. – № 56(4) – P. 295–7.101.GobecS.Synthesisofnewlipophilicphosphonateandphosphonamidate analogues of N-acetyl muramyl-L-alanul-D-isoglutamine relatedto LK423 Molecules / S. Gobec, U. Urleb //– 2002. – №7 – P. 394–404.102.Goto S. Combined immunocell therapy using activated lymphocytesand monocyte-derived dendritic cells for malignant melanoma / T. Kaneko, Y.Miyamoto, M. Eriguchi, A.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
